Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors

References

• Abeyweera TP, Merino E, Huse M. Inhibitory signaling blocks activating receptor clustering and induces cytoskeletal retraction in natural killer cells. J Cell Biol 2011; 192:675-90; PMID:21339333; http://dx.doi.org/10.1083/jcb.201009135
   PubMed Web of Science ®Google Scholar
• Adair JR, Athwal DS, Bodmer MW, Bright SM, Collins AM, Pulito VL, Rao PE, Reedman R, Rothermel AL, Xu D et al. Humanization of the murine anti-human CD3 monoclonal antibody OKT3. Hum Antibodies Hybridomas 1994; 5:41-7; PMID:7858182; http://dx.doi.org/10.3233/HAB-1994-51-206
   PubMedGoogle Scholar
• Ahmed M, Cheng M, Cheung I, Cheung NK. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody. OncoImmunology 2015; 4:e989776; PMID:26137406; http://dx.doi.org/10.4161/2162402X.2014
   PubMed Web of Science ®Google Scholar
• Ahmed M, Cheung NK. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett 2014; 588:288-97; PMID:24295643; http://dx.doi.org/10.1016/j.febslet.2013.11.030
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321:974-7; PMID:18703743; http://dx.doi.org/10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Bluemel C, Hausmann S, Fluhr P, Sriskandarajah M, Stallcup WB, Baeuerle PA, Kufer P. Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen. Cancer Immunol Immunother 2010; 59:1197-209; PMID:20309546; http://dx.doi.org/10.1007/s00262-010-0844-y
   PubMed Web of Science ®Google Scholar
• Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737
   PubMed Web of Science ®Google Scholar
• Cheng M, Ahmed M, Xu H, Cheung NK. Potency and structural design of disialoganglioside and CD3-bispecific antibodies for redirecting T cells for tumor therapy. Int J Cancer 2014; 136:476-486; PMID:24895182; http://dx.doi.org/10.1002/ijc.29007
   PubMed Web of Science ®Google Scholar
• Cheng M, Ahmed M, Xu H, Cheung NK. Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. Int J Cancer 2015; 136:476-86; PMID:24895182; http://dx.doi.org/10.1002/ijc.29007
   PubMed Web of Science ®Google Scholar
• Cheung NK, Cheung IY, Kushner BH, Ostrovnaya I, Chamberlain E, Kramer K, Modak S. Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-Cis-Retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. J Clin Oncol 2012a; 30:3264-70; PMID:22869886; http://dx.doi.org/10.1200/JCO.2011.41.3807
   PubMed Web of Science ®Google Scholar
• Cheung NK, Guo H, Hu J, Tassev DV, Cheung IY. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo. OncoImmunology 2012b; 1:477-86; PMID:22754766; http://dx.doi.org/10.4161/onci.19864
   PubMed Web of Science ®Google Scholar
• Choi BD, Kuan CT, Cai M, Archer GE, Mitchell DA, Gedeon PC, Sanchez-Perez L, Pastan I, Bigner DD, Sampson JH. Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma. Proc Natl Acad Sci USA 2013; 110:270-5; PMID:23248284; http://dx.doi.org/10.1073/pnas.1219817110
   PubMed Web of Science ®Google Scholar
• Cioffi M, Dorado J, Baeuerle PA, Heeschen C. EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18:465-74; PMID:22096026; http://dx.doi.org/10.1158/1078-0432.CCR-11-1270
   PubMed Web of Science ®Google Scholar
• Dobrenkov K, Cheung NK. GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol 2014; 41:589-612; PMID:25440605; http://dx.doi.org/10.1053/j.seminoncol.2014.07.003
   PubMed Web of Science ®Google Scholar
• Ewert S, Honegger A, Pluckthun A. Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering. Methods 2004; 34:184-99; PMID:15312672; http://dx.doi.org/10.1016/j.ymeth.2004.04.007
   PubMed Web of Science ®Google Scholar
• Hagihara Y, Saerens D. Engineering disulfide bonds within an antibody. Biochim Biophys Acta 2014; 1844:2016-23; PMID:25038323; http://dx.doi.org/10.1016/j.bbapap.2014.07.005
   PubMed Web of Science ®Google Scholar
• Kipriyanov SM, Moldenhauer G, Schuhmacher J, Cochlovius B, Von der Lieth CW, Matys ER, Little M. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 1999; 293:41-56; PMID:10512714; http://dx.doi.org/10.1006/jmbi.1999.3156
   PubMed Web of Science ®Google Scholar
• Le Gall F, Reusch U, Little M, Kipriyanov SM. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004; 17:357-66; PMID:15126676; http://dx.doi.org/10.1093/protein/gzh039
   PubMed Web of Science ®Google Scholar
• Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, Croner LJ, Wang N, Amatucci A, Michaelson JS et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
   PubMed Web of Science ®Google Scholar
• Orcutt KD, Slusarczyk AL, Cieslewicz M, Ruiz-Yi B, Bhushan KR, Frangioni JV, Wittrup KD. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. Nucl Med Biol 2011; 38:223-33; PMID:21315278; http://dx.doi.org/10.1016/j.nucmedbio.2010.08.013
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Spiess C, Zhai Q, Carter PJ. Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol 2015; 67:95-106; PMID:25637431; http://dx.doi.org/10.1016/j.molimm.2015.01.003
   PubMed Web of Science ®Google Scholar
• Suzuki M, Cheung NK. Disialoganglioside GD2 as a therapeutic target for human diseases. Expert Opin Ther Targets 2015; 19:349-62; PMID:25604432; http://dx.doi.org/10.1517/14728222.20.986459
   PubMed Web of Science ®Google Scholar
• Thakkar S, Nanaware-Kharade N, Celikel R, Peterson EC, Varughese KI. Affinity improvement of a therapeutic antibody to methamphetamine and amphetamine through structure-based antibody engineering. Sci Rep 2014; 4:3673; PMID:24419156; http://dx.doi.org/10.1038/srep03673
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC, Dombret H, Fielding AK, Heffner L, Larson RA et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16:57-66; PMID:25524800; http://dx.doi.org/10.1016/S1470-2045(14)71170-2
   PubMed Web of Science ®Google Scholar
• Torisu-Itakura H, Schoellhammer HF, Sim MS, Irie RF, Hausmann S, Raum T, Baeuerle PA, Morton DL. Redirected lysis of human melanoma cells by a MCSP/CD3-bispecific BiTE antibody that engages patient-derived T cells. J Immunother 2011; 34:597-605; PMID:21904216; http://dx.doi.org/10.1097/CJI.0b013e3182307fd8
   PubMed Web of Science ®Google Scholar
• Wiedermann U, Davis AB, Zielinski CC. Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines. Breast Cancer Res Treat 2013; 138:1-12; PMID:23340862; http://dx.doi.org/10.1007/s10549-013-2410-8
   PubMed Web of Science ®Google Scholar
• Xu H, Cheng M, Guo H, Chen Y, Huse M, Cheung NK. Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody. Cancer Immunol Res 2015; 3:266-77; PMID:25542634; http://dx.doi.org/10.1158/2326-6066.CIR-14-0230-T
   PubMed Web of Science ®Google Scholar
• Yankelevich M, Kondadasula SV, Thakur A, Buck S, Cheung NK, Lum LG. Anti-CD3 x anti-GD2 bispecific antibody redirects T-cell cytolytic activity to neuroblastoma targets. Pediatr Blood Cancer 2012; 59:1198-205; PMID:22707078; http://dx.doi.org/10.1002/pbc.24237
   PubMed Web of Science ®Google Scholar
• Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, Smith M, Anderson B, Villablanca JG, Matthay KK et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010; 363:1324-34; PMID:20879881; http://dx.doi.org/10.1056/NEJMoa0911123
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ahmed M, Guo HF, Cheung IY, Cheung NK. Alteration of electrostatic surface potential enhances affinity and tumor killing properties of anti-ganglioside GD2 monoclonal antibody hu3F8. J Biol Chem 2015; 290:13017-27; PMID:25851904; http://dx.doi.org/10.1074/jbc.M115.650903
   PubMed Web of Science ®Google Scholar